

Genetic risk factors for late age-related macular degeneration in India

Anand Rajendran,¹ Pankaja Dhoble,² Periasamy Sundaresan,³ Vijayan Saravanan,³ Praveen Vashist,⁴ Dorothea Nitsch,⁵ Liam Smeeth,⁵ Usha Chakravarthy,⁶ Ravilla D Ravindran,¹ Astrid E Fletcher⁵

ABSTRACT

¹Aravind Eye Hospital, Madurai, Tamil Nadu, India ²Aravind Eve Hospital, Pondicherry, Tamil Nadu, India ³Department of Genetics, Dr G Venkataswamy Research Institute, Aravind Medical Research Foundation, Madurai, Tamil Nadu, India ⁴Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India ⁵Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK ⁶Centre for Public Health, Queen's University, Belfast, UK

Correspondence to

Professor Astrid E Fletcher, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK; astrid.fletcher@lshtm.ac.uk

Received 25 September 2017 Revised 24 November 2017 Accepted 4 December 2017 Published Online First 19 December 2017 **Background/Aims** There are limited data from India on genetic variants influencing late age-related macular degeneration (AMD). We have previously reported associations from a population-based study in India (the India age-related eye disease study (INDEYE)) of early AMD and single nucleotide polymorphisms (SNPs) in *ARMS2/HTRA1* and no association with *CFH*, *C2* or *CFB*. Late AMD cases were too few for meaningful analyses. We aimed to investigate SNPs for late AMD through case enrichment and extend the loci for early AMD.

Methods Fundus images of late AMD hospital cases were independently graded by the modified Wisconsin AMD grading scheme. In total 510 cases with late AMD (14 geographic atrophy and 496 neovascular AMD (nvAMD)), 1876 with early AMD and 1176 with no signs of AMD underwent genotyping for selected SNPs. We investigated genotype and per-allele additive associations (OR and 95% CIs) with nvAMD or early AMD. Bonferroni adjusted P values are presented. **Results** We found associations with nvAMD for CFHY402H variant (rs1061170) (OR=1.99, 95% CI 1.67 to 2.37, P=10⁻⁶), ARMS2 (rs10490924) (OR=2.94, 95% CI 2.45 to 3.52, P=10⁻⁹), C2 (rs547154) (OR=0.67, 95% CI 0.53 to 0.85, P=0.01), ABCA1 (rs1883025) (OR=0.77, 95% CI 0.65 to 0.92, P=0.04) and an SNP near VEGFA (rs4711751) (OR=0.64, 95% CI 0.54 to 0.77, $P=10^{-3}$). We found no associations of *TLR3* (rs3775291), CFD (rs3826945), FRK (rs1999930) or LIPC (rs10468017) or APOE ɛ4 alleles with nvAMD or early AMD, nor between early AMD and rs1883025 or rs4711751.

Conclusions The major genetic determinants of nvAMD risk in India are similar to those in other ancestries, while findings for early AMD suggest potential differences in the pathophysiology of AMD development.

INTRODUCTION

Genetic risk variants for late age-related macular degeneration (AMD) have been identified and further confirmed in genome-wide association studies (GWAS), the majority of which in studies of European ancestry.¹ There is less information on late AMD genetic risk in India, with most data coming from one patient/control cohort.^{2–4} We have previously reported genetic results from a large population-based study of people aged 60 and over in India (the India age-related eye disease study (INDEYE)) for early AMD with variants in complement factor H (*CFH*), factor B (*CFB*), component 2 (*C2*) and


*ARMS2/HTRA1.*⁵ Late AMD cases were too few for meaningful analyses. In the present paper we present results for late AMD based on an enriched sample and for other genetic loci with early AMD.

MATERIALS AND METHODS

INDEYE was conducted between 2005 and 2007 in two locations in south (Tamil Nadu) and north (Haryana) India. The study methods including sampling and recruitment, blood collection, ophthalmological examination and AMD grading, along with results on the prevalence of early and late AMD, have been published.⁶ In the present study, we recruited additional cases of late AMD between 2009 and 2011 from the hospitals that participated in the INDEYE study (All India Institute of Medical Sciences, Delhi, and Aravind Eye Hospital, Pondicherry, Tamil Nadu) and additionally from Aravind Eye Hospital, Madurai, Tamil Nadu. We aimed to achieve 600 late AMD cases plus two population controls per case to detect the twofold per-allele association of Y402H CFH (rs1061170) reported in a meta-analysis of primarily European ancestry⁷ at 90% power and alpha <0.001. Initial eligibility criteria were age 60 years and over, Indian descent and a diagnosis of late AMD by retinal ophthalmologists. Controls were participants in the INDEYE study with no signs of early or late AMD in either eye.

In both INDEYE and clinic participants, informed written consent was obtained prior to enrolment. If the participant was illiterate, the information sheet was read out aloud in the presence of a local witness, and a thumb impression of the participant signified assent. The study complied with the Declaration of Helsinki.

Full details of the method of ascertainment of AMD in the population study have previously been published.⁶ In brief two 35° stereo fundus photographs of each eye were taken and graded at Queens University Belfast (QUB) using the modified Wisconsin Age-Related Maculopathy Grading System.⁸ Each eye was classified into four mutually exclusive grades: grade 1: soft distinct drusen $(\geq 63 \,\mu\text{m})$ only or pigmentary irregularities only; grade 2: soft indistinct ($\geq 125 \,\mu m$) or reticular drusen only or soft distinct drusen ($\geq 63 \,\mu m$) with pigmentary irregularities; grade 3: soft indistinct $(\geq 125 \text{ um})$ or reticular drusen with pigmentary irregularities; grade 4: either neovascular AMD (nvAMD; presence of any of the following: serous or haemorrhagic retinal or retinal pigment epithelial



To cite: Rajendran A, Dhoble P, Sundaresan P, *et al. Br J Ophthalmol* 2018;**102**:1213–1217. detachment, subretinal neovascular membrane, periretinal fibrous scar) or geographic atrophy (GA; well-demarcated area of retinal pigment atrophy with visible choroidal vessels). Fundus images of cases recruited from hospital clinics were sent to QUB (colour photographs, optical coherence tomography (OCT)) and graded as above. In all graded images, GA and nvAMD present in the same eye were categorised as nvAMD. Images that showed no signs of any features of early or late AMD were categorised as having no AMD.

DNA extraction and genotyping

Genomic DNA was extracted from peripheral blood nucleotide leucocytes using Qiagen kits. Single polymorphisms (SNPs) were genotyped using TagMan assays in an ABI 7900 real-time PCR. We limited our study to genes in biological pathways relevant to AMD pathogenesis, including complement activation (CFH, CFB, CFD) and deposition (Toll-like receptors (TLR 3, 4, 7)), lipid metabolism (ABCA1, APOE, CETP, LIPC), or the degradation of the extracellular matrix (TIMP3).9 We investigated two SNPs on chromosome 6, previously reported to be associated with late AMD¹⁰ (LOC107986598 rs4711751 located near VEGFA and FRK rs1999930 near COL10A1). We included SNPs in ARMS2/ HTRA1 due to their demonstrated importance in many studies¹¹ and recent evidence for an ARMS2 role in surface complement regulation.¹² We tested for departures from Hardy-Weinberg equilibrium (HWE) in controls and excluded any SNPs with a P value ≤ 0.05 . We used logistic regression in Stata V.14 to examine associations of (1) genotype and (2) per-allele additive models adjusted for age, sex and centre. We present additionally Bonferroni-adjusted P values for the number of independent SNPs tested. We created *APOE* alleles from the SNPs rs429358 (T/C) and rs7412 (C/T), resulting in three alleles: $\epsilon 2$ (TT), $\epsilon 3$ (TC) and $\epsilon 4$ (CC). Analyses of *APOE* alleles used $\epsilon 3$ as the reference group.

RESULTS

The prevalence of early and late AMD in the INDEYE population study has been published.⁶ There were 1986 cases of early AMD (1686 grade 1, 289 grade 2, 11 grade 3), 53 of late AMD (44 nvAMD, 9 GA) and 1228 population controls with no signs of AMD in either eye. Hospital retinal clinics recruited 533 cases based on ophthalmologists' diagnoses. After exclusion of participants without confirmed late AMD or missing blood samples (figure 1), 496 nvAMD cases, 1876 early AMD and 1176 controls were available for analysis. We did not investigate GA because of a small number (n=14). The mean age in years (SD) was 65.3 (5.4) in population controls, in early AMD 67.0 (6.1) and in nvAMD 70.7 (6.9). The number and proportion of women were 600 (51%), 915 (49%) and 179 (36%), respectively. Two SNPs




Figure 1 Flow chart of hospital case recruitment and population cases and controls. AMD, age-related macular degeneration; OCT, optical coherence tomography.

Chromosome	Gene	SNP	Major/minor alleles	HWE*	MAFt	MAF EUR‡	MAF SAS§
1	Y402H	rs1061170	T/C	0.6854	0.323	0.362	0.287
4	TLR3	rs3775291	C/T	0.9347	0.235	0.324	0.263
6	C2	rs547154	C/A	0.3813	0.187	0.089	0.156
6	SKIV2L	rs438999	A/G	0.6932	0.183	0.089	0.148
6	<i>LOC107986598</i> ¶	rs4711751	T/C	1	0.423	0.487	0.330
6	FRK	rs1999930	C/T	0.3957	0.075	0.281	0.052
9	ABCA1	rs1883025	C/T	0.0797	0.432	0.240	0.413
10	ARMS2	rs10490923	G/A	0.7299	0.149	0.130	0.148
10	ARMS2	rs10490924	G/T	0.1953	0.319	0.195	0.343
10	HTRA1	rs2672598	T/C**	0.2969	0.524	0.499	0.464
15	LIPC	rs10468017	C/T	0.9195	0.176	0.283	0.184
16	CETP	rs3764261	C/A	0.0737	0.295	0.292	0.321
19	APOE	rs429358	T/C	1	0.097	0.155	0.087
19	APOE	rs7412	C/T	0.5232	0.050	0.063	0.044
19	CFD	rs3826945	T/C	0.8424	0.344	0.313	0.334

*P value for tests for departure from Hardy-Weinberg equilibrium (HWE) in controls.

†Minor allele frequency (MAF) in controls.

#MAF from 1000 genome study for European ancestry available at https://www.ncbi.nlm.nih.gov/snp.

§MAF from 1000 genome study for South Asian ancestry available at https://www.ncbi.nlm.nih.gov/snp.

¶SNP located near VEGFA.

**Minor allele considered as C for comparison with other studies.

SNP, single nucleotide polymorphisms.

(rs4986790 *TLR4/TLR7*, rs9621532 *TIMP3*) failed HWE. HWE and minor allele frequencies (MAFs) for the remaining SNPs are shown in table 1. We also present MAFs for European and Indian ancestries from the 1000 genome study (https://www.ncbi.nlm. nih.gov/snp, accessed 5 December 2016). The control frequencies of *APOE* alleles were ε 3 (0.73), ε 2 (0.09) and ε 4 (0.18).

We found additive associations with nvAMD for Y402H (rs1061170), HTRA1 (rs2672598), ARMS2 (rs10490924, rs10490923), CFB (rs438999, rs547154), ABCA1 (rs1883025) and SNP (rs4711751 close to VEGFA) (table 2). We found no associations with TLR3 (rs3775291), CFD (rs3826945), FRK (rs1999930) or LIPC (rs10468017). There was no association

between APOE ϵ 4 and nvAMD (OR=0.72, 95%CI 0.52 to 1.01).

We combined grades 2 and 3 of early AMD due to the small numbers of grade 3. Subsequently we combined all grades of early AMD (1–3) because our preliminary analyses revealed no differences in genetic associations for these early stages. There were no associations with early AMD and any of the SNPs (table 3) or with *APOE* ε 4 (OR=0.88, 95% CI 0.73 to 1.01).

DISCUSSION

CFH and *ARMS2/HTRA1* have been identified in numerous studies in European^{1 11} and East Asian ancestries¹³ as the most

Table 2 Association of neovascular age-related macular degeneration with SNPs

			1 vs 0 copy of minor allele		2 vs 0 copies of minor allele		Additive per minor allele			
Gene	SNP	Major/minor alleles	OR*	95% CI	OR*	95% CI	OR*	95% CI	Р	Pt
Y402H	rs1061170	T/C	1.72	1.31 to 2.28	4.13	2.91 to 5.87	1.99	1.67 to 2.37	10 ⁻⁷	10 ⁻⁶
TLR3	rs3775291	C/T	1.18	0.92 to 1.51	0.88	0.51 to 1.53	1.06	0.87 to 1.30	0.545	
C2	rs547154	C/A	0.62	0.47 to 0.82	0.64	0.29 to 1.43	0.67	0.53 to 0.85	0.001	0.01
SKIV2L	rs438999	A/G	0.63	0.47 to 0.83	0.50	0.21 to 1.22	0.65	0.50 to 0.83	0.001	0.01
LOC107986598	rs4711751	T/C	0.35	0.27 to 0.46	0.65	0.45 to 0.94	0.64	0.54 to 0.77	10 ⁻⁴	10 ⁻³
FRK	rs1999930	C/T	0.93	0.64 to 1.34	5.94	1.17 to 30.10	1.05	0.74 to 1.49	0.777	
ABCA1	rs1883025	C/T	0.81	0.61 to 1.07	0.58	0.41 to 0.83	0.77	0.65 to 0.92	0.003	0.04
ARMS2	rs10490923	G/A	0.49	0.35 to 0.67	0.85	0.33 to 2.17	0.57	0.43 to 0.75	10 ⁻³	0.04
ARMS2	rs10490924	G/T	1.86	1.37 to 2.51	8.73	6.11 to 12.48	2.94	2.45 to 3.52	10 ⁻¹⁰	10 ⁻⁹
HTRA1	rs2672598	T/C	1.53	1.01 to 2.32	5.42	3.58 to 8.21	2.67	2.19 to 3.25	10 ⁻⁹	10 ⁻⁸
LIPC	rs10468017	C/T	1.13	0.87 to 1.47	1.12	0.56 to 2.23	1.11	0.89 to 1.37	0.370	
CETP	rs3764261	C/A	1.27	0.98 to 1.64	1.26	0.82 to 1.91	1.17	0.98 to 1.41	0.087	
APOE	rs429358	T/C	0.82	0.60 to 1.14	NC‡		NC‡			
APOE	rs7412	C/T	0.87	0.58 to 1.32	NC‡		NC‡			
CFD	rs3826945	T/C	1.02	0.79 to 1.31	1.05	0.70 to 1.58	1.02	0.85 to 1.23	0.820	

*Adjusted for age, sex and centre.

†Bonferroni-adjusted P value for 13 per-allele tests.

\$Not calculated, no cases with 2 copies of minor allele.

SNP, single nucleotide polymorphisms.

Gene	SNP	1 vs 0 copy of minor allele			2 vs 0 co	2 vs 0 copies of minor allele			Additive per allele		
		OR*	95% CI	Р	OR*	95% CI	Р	OR*	95% CI	Р	
TLR3	rs3775291	1.01	0.86 to 1.20	0.868	1.13	0.83 to 1.54	0.425	1.04	0.92 to 1.16	0.520	
LOC107986598	rs4711751	0.95	0.78 to 1.14	0.558	0.91	0.69 to 1.20	0.502	0.95	0.84 to 1.08	0.452	
FRK	rs1999930	0.83	0.66 to 1.05	0.117	1.63	0.39 to 6.77	0.498	0.88	0.69 to 1.12	0.285	
ABCA1	rs1883025	0.96	0.79 to 1.17	0.698	0.96	0.77 to 1.19	0.726	0.98	0.88 to 1.09	0.699	
LIPC	rs10468017	0.97	0.82 to 1.14	0.677	1.08	0.67 to 1.75	0.744	0.99	0.85 to 1.15	0.913	
CETP	rs3764261	1.08	0.91 to 1.28	0.365	1.10	0.90 to 1.33	0.339	1.06	0.96 to 1.17	0.228	
APOE	rs429358	0.93	0.77 to 1.12	0.454	0.80	0.35 to 1.84	0.594	0.93	0.77 to 1.10	0.380	
APOE	rs7412	0.97	0.74 to 1.27	0.826	1.38	0.42 to 4.55	0.594	1.00	0.79 to 1.27	0.994	
CFD	rs3826945	1.02	0.88 to 1.20	0.758	1.10	0.87 to 1.39	0.399	1.04	0.94 to 1.15	0.416	

 Table 3
 Association of early age-related macular degeneration with SNPs

*Adjusted for age, sex and centre.

SNP, single nucleotide polymorphism.

important genes for late AMD risk, with effect sizes around 2.5 and 3 per allele, respectively,¹⁷¹¹ and the top two variants at GWAS significance.¹ Our effect sizes of 2 for the C allele of *Y402H* variant of *CFH* (rs1061170) and 3 for *ARMS2* T allele (rs10490924) are consistent with these findings and add to the limited evidence for India.^{2 3} The MAF of rs1061170 is lower in East Asian (<0.10) compared with European ancestry (0.3),⁷ and higher for rs10490924 (0.4), almost twice that in European ancestry.⁹ Our MAFs for rs1061170 (0.32) and rs10490924 (0.32) concur with those for South Asians in the 1000 genome study (table 1) and other sources in India.^{2 3 14} It appears that rs1061170 allele frequencies in Indian ancestry are closer to European than East Asian for rs10490924.

We found associations with SNPs in other genes established predominantly in European ancestry, including C2, *SKIV2L* and *ABCA1* and in an SNP (rs4711751) in an uncharacterised gene *LOC107986598* close to *VEGFA*.¹ We found a reduced risk with the T allele of *ABCA1* (rs1883025) but not with *CETP* or *LIPC*. A meta-analysis of European ancestry studies found *APOE* £4 haplotype was associated with a 30% lower risk of nvAMD¹⁵; we observed a similar effect but with wide CIs.

We found no association with early AMD and any of the variants reported in table 3. We have previously reported results for early AMD and found no association with Y402H (rs1061170), C2 (rs547154) and SKIVL (rs43899).⁵ ARMS2/ HTRA1 variants (rs10490924 and rs2672598) were associated with early AMD; the OR per allele was 1.22 (95% CI 1.13 to 1.33, P<0.0001) and 1.12 (95% CI 1.02 to 1.23, P=0.02), respectively.⁵ A GWAS meta-analysis of 4089 early AMD cases, the majority of European ancestry, found associations between SNPs in CFH and ARMS2/HTRA1, but with smaller effect sizes than those reported for late AMD.¹⁶ Analyses by Asian ancestry found no association with any CFH SNP, whereas ARMS2 (rs10490924) was associated with an OR of 1.18 (95% CI 1.07 to 1.13), similar to our study, compared with 1.43 (95% CI 1.34 to 1.54) for European ancestry. The lower prevalence of early AMD in Asia¹⁷ and India⁶ may, in part, be explained by the apparently lesser role of genetic variants compared with studies in European ancestry, but caution is warranted due to the paucity of genetic studies of early AMD in Indian and East Asian ancestries.

Limitations

Although we did not attain the 600 planned cases, we confirmed the per-allele twofold risk of rs1061170 and nvAMD

hypothesised for the sample size estimates. We had low power to investigate variants with low MAFs (compared with European ancestry) such as *FRK* and *LIPC*, or to identify smaller effects. The majority of late AMD cases were of nvAMD phenotype, similar to studies in East Asia,¹⁸ and we could not investigate genetic associations with GA. It is possible we misclassified population cases of late AMD. We had confirmatory OCTs in 89% of clinical late AMD cases, but the population-based study used colour images only.

CONCLUSIONS

Our findings suggest the major genetic determinants of nv AMD risk in India are similar to those in other populations, while findings for early AMD suggest potential differences in the pathophysiology of AMD development.

Contributors AEF had full access to all the data in the study and takes full responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: AEF, RDR, UC, LS, DN. Acquisition, analysis or interpretation of data: all authors. Drafting of the manuscript: AEF, RDR. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: AEF. Obtained funding: AEF, UC, RDR, DN, LS. Administrative, technical or material support: RDR, UC, PS, AEF. Study supervision: RDR, AEF.

Funding Wellcome Trust UK Grants G073300 and G082571.

Competing interests None declared.

Ethics approval Ethics approval was received from the Indian Council for Medical Research, the Research Ethics Committees of All India Institute of Medical Sciences (AIIMS) Delhi, Aravind Eye Hospital Pondicherry (Tamil Nadu), Aravind Eye Hospital Madurai (Tamil Nadu), the London School of Hygiene & Tropical Medicine, and Queen's University Belfast.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide association study of agerelated macular degeneration highlights contributions of rare and common variants. Nat Genet 2016;48:134–43.
- 2 Kaur I, Hussain A, Hussain N, et al. Analysis of CFH, TLR4, and APOE polymorphism in India suggests the Tyr402His variant of CFH to be a global marker for age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2006;47:3729–35.
- 3 Kaur I, Katta S, Hussain A, *et al.* Variants in the 10q26 gene cluster (LOC387715 and HTRA1) exhibit enhanced risk of age-related macular degeneration along with CFH in Indian patients. *Invest Ophthalmol Vis Sci* 2008;49:1771–6.

- 4 Kaur I, Katta S, Reddy RK, et al. The involvement of complement factor B and complement component C2 in an Indian cohort with age-related macular degeneration. Invest Ophthalmol Vis Sci 2010;51:59–63.
- 5 Sundaresan P, Vashist P, Ravindran RD, et al. Polymorphisms in ARMS2/HTRA1 and complement genes and age-related macular degeneration in India: findings from the INDEYE study. Invest Ophthalmol Vis Sci 2012;53:7492–7.
- 6 Krishnan T, Ravindran RD, Murthy GV, et al. Prevalence of early and late agerelated macular degeneration in India: the INDEYE study. *Invest Ophthalmol Vis Sci* 2010;51:701–7.
- 7 Sofat R, Casas JP, Webster AR, *et al*. Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype. *Int J Epidemiol* 2012;41:250–62.
- 8 Bird AC, Bressler NM, Bressler SB, *et al*. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The international ARM epidemiological study group. *Surv Ophthalmol* 1995;39:367–74.
- 9 Fritsche LG, Fariss RN, Stambolian D, et al. Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet 2014;15:151–71.
- 10 Yu Y, Bhangale TR, Fagerness J, *et al.* Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration. *Hum Mol Genet* 2011;20:3699–709.

- 11 Fritsche LG, Chen W, Schu M, et al. Seven new loci associated with age-related macular degeneration. Nat Genet 2013;45:433–9.
- 12 Micklisch S, Lin Y, Jacob S, *et al*. Age-related macular degeneration associated polymorphism rs10490924 in ARMS2 results in deficiency of a complement activator. *J Neuroinflammation* 2017;14:4.
- 13 Cheng CY, Yamashiro K, Chen LJ, *et al*. New loci and coding variants confer risk for age-related macular degeneration in East Asians. *Nat Commun* 2015;6:6063.
- 14 Pemberton TJ, Mehta NU, Witonsky D, et al. Prevalence of common disease-associated variants in Asian Indians. BMC Genet 2008;9:13–20.
- 15 McKay GJ, Patterson CC, Chakravarthy U, *et al*. Evidence of association of APOE with age-related macular degeneration: a pooled analysis of 15 studies. *Hum Mutat* 2011;32:1407–16.
- 16 Holliday EG, Smith AV, Cornes BK, et al. Insights into the genetic architecture of early stage age-related macular degeneration: a genome-wide association study metaanalysis. PLoS One 2013;8:e53830.
- 17 Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and metaanalysis. Lancet Glob Health 2014;2:e106–e116.
- 18 Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2010;117:921–7.